Stock OBI ONDINE BIOMEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Delayed London S.E.
Other stock markets
 04:31:16 2024-06-04 am EDT 		5-day change 1st Jan Change
8.165 GBX -2.80% Intraday chart for Ondine Biomedical Inc. +5.35% -6.69%
May. 08 Hellenic Dynamics and Ondine Biomedical raise funds AN
May. 03 Ondine Biomedical shares rise on fundraise to advance Steriwave AN

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ONDINE BIOMEDICAL INC. Stock Ondine Biomedical Inc.
-6.69% 29.79M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.54% 179B
C+
MEDTRONIC PLC Stock Medtronic plc
-0.32% 108B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-2.05% 69.03B
A
DEXCOM, INC. Stock DexCom, Inc.
-7.14% 45.83B
B-
CENCORA, INC. Stock Cencora, Inc.
+12.24% 45.39B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.60% 43.17B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.37% 29.89B
B
TERUMO CORPORATION Stock Terumo Corporation
+13.65% 25.49B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.64% 23.95B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
  1. Stock Market
  2. Equities
  3. OBI Stock
  4. Ratings Ondine Biomedical Inc.